IDEXX LABORATORIES INC /DE — Director's Dealing 2021

Aug 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-08-03

Reporting Person: Lane Michael (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-03	Common Stock	M	1472	$67.85	Acquired	5119.2845	Direct
2021-08-03	Common Stock	M	1091	$67.85	Acquired	6210.2845	Direct
2021-08-03	Common Stock	M	4436	$141.6	Acquired	10646.2845	Direct
2021-08-03	Common Stock	S	2451	$690.1997	Disposed	8195.2845	Direct
2021-08-03	Common Stock	S	250	$691.5368	Disposed	7945.2845	Direct
2021-08-03	Common Stock	S	363	$692.8467	Disposed	7582.2845	Direct
2021-08-03	Common Stock	S	1447	$693.7287	Disposed	6135.2845	Direct
2021-08-03	Common Stock	S	916	$694.7894	Disposed	5219.2845	Direct
2021-08-03	Common Stock	S	100	$695.5	Disposed	5119.2845	Direct
2021-08-03	Common Stock	S	95	$687.4650	Disposed	5024.2845	Direct
2021-08-03	Common Stock	S	245	$688.5444	Disposed	4779.2845	Direct
2021-08-03	Common Stock	S	245	$689.4310	Disposed	4534.2845	Direct
2021-08-03	Common Stock	S	30	$690.3250	Disposed	4504.2845	Direct
2021-08-03	Common Stock	S	100	$691.3520	Disposed	4404.2845	Direct
2021-08-03	Common Stock	S	60	$692.6466	Disposed	4344.2845	Direct
2021-08-03	Common Stock	S	84	$687.5931	Disposed	4280.2845	Direct
2021-08-03	Common Stock	S	299	$688.5104	Disposed	3961.2845	Direct
2021-08-03	Common Stock	S	153	$689.5101	Disposed	3808.2845	Direct
2021-08-03	Common Stock	S	100	$691.192	Disposed	3708.2845	Direct
2021-08-03	Common Stock	S	60	$692.5616	Disposed	3648.2845	Direct
2021-08-03	Common Stock	S	1	$693.17	Disposed	3647.2845	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-03	Incentive Stock Option (right-to-buy)	$67.85	M	1472	Disposed	2026-02-13	Common Stock (1472)	Direct
2021-08-03	Non-Qualified Stock Option (right-to-buy)	$67.85	M	1091	Disposed	2026-02-13	Common Stock (1091)	Direct
2021-08-03	Non-Qualified Stock Option (right-to-buy)	$141.60	M	4436	Disposed	2027-02-13	Common Stock (4436)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	592	Indirect

Footnotes

F1: Includes a total of 23.2845 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021 and June 30, 2021.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $690.00 to a high of $690.965 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $691.085 to a high of $692.08 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sales price of the shares sold ranging from a low of $692.33 to a high of $693.26 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: Represents the weighted average sales price of the shares sold ranging from a low of $693.38 to a high of $694.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: Represents the weighted average sales price of the shares sold ranging from a low of $694.49 to a high of $695.375 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F7: Represents the weighted average sales price of the shares sold ranging from a low of $686.91 to a high of $687.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F8: Represents the weighted average sales price of the shares sold ranging from a low of $688.07 to a high of $688.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F9: Represents the weighted average sales price of the shares sold ranging from a low of $689.14 to a high of $690 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F10: Represents the weighted average sales price of the shares sold ranging from a low of $690.17 to a high of $690.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F11: Represents the weighted average sales price of the shares sold ranging from a low of $691.19 to a high of $691.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F12: Represents the weighted average sales price of the shares sold ranging from a low of $692.27 to a high of $692.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F13: Represents the weighted average sales price of the shares sold ranging from a low of $687.05 to a high of $687.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F14: Represents the weighted average sales price of the shares sold ranging from a low of $688.09 to a high of $688.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F15: Represents the weighted average sales price of the shares sold ranging from a low of $689.25 to a high of $690.18 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F16: Represents the weighted average sales price of the shares sold ranging from a low of $690.45 to a high of $691.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F17: Represents the weighted average sales price of the shares sold ranging from a low of $692.125 to a high of $692.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F18: Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

F19: Grant of option to buy 2,072 shares of Issuer common stock that vested in five annual installments beginning February 14, 2017.

F20: Grant of option to buy 10,749 shares of Issuer common stock that vested in five annual installments beginning February 14, 2017.

F21: Grant of option to buy 10,386 shares of Issuer common stock that vest in five annual installments beginning February 14, 2018.

F22: Not applicable.